Denied Cancer Drug Appeals: Reviewer Outcomes

A physician-administered oncology agent given by infusion and billed under its own supply code — the medical benefit. Monoclonal antibodies and other infused agents dominate this group.

What the independent reviewers decided

46%

overturned by the independent reviewer

of 145 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny infused cancer drug

The policy covers the agent only at a specified line of therapy and the record does not establish which line this is.
The requested use is off-label and the policy limits coverage to labelled indications or named compendia.
A biomarker or molecular result the policy requires is absent from the file.
The combination requested is not one the policy recognises.

What actually carried the cases that won

Prior treatment dominated, and in this group it means the line of therapy specifically: what was given before, in what order, and what happened. The overturned records established the sequence as a fact rather than a summary. Peer-reviewed literature and clinical guidelines were the two authorities reviewers leaned on, which makes a compendium or guideline reference for the requested line the natural spine of the appeal.

What the record showed	Share of overturned decisions
Prior treatment was documented	87%
A published guideline supported the request	42%
The severity or urgency was documented	21%
Conservative treatment was documented as failed	18%
The diagnosis was confirmed	12%
Objective findings were documented	7%
The functional impact on the patient was documented	7%
The condition was documented as chronic or long-standing	7%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 52% of the overturned decisions
Clinical guidelines — in 46% of the overturned decisions
Specialty-society criteria — in 43% of the overturned decisions
FDA labeling — in 33% of the overturned decisions
Standard of care — in 6% of the overturned decisions

infused cancer drug denials — frequently asked

Is a denied infused cancer drug worth appealing?

46% of 145 California independent medical reviews were overturned — slightly under half. Oncology denials in this corpus were more evenly contested than the infused-biologic group.

What does the record need to establish first?

The line of therapy. Which regimens were given, in what order, over what dates, and why each stopped. Policies that cover an agent at second line will not read a summary that says the patient has been heavily pretreated as establishing that this is second line.

How are off-label requests treated?

They turn on whether the policy recognises a compendium or guideline that supports the use. Where it does, naming the specific entry is what moves the dispute; where it does not, the appeal is arguing against the policy's evidence standard, which is a harder case.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →